Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Oct 24;32(11):596.
doi: 10.3390/curroncol32110596.

Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer

Riccardo Vida  1   2 , Michele Bartoletti  2 , Lucia Lerda  3 , Serena Corsetti  2 , Simona Scalone  2 , Anna Calabrò  4 , Angela Caroli  5 , Monica Rizzetto  1   2 , Giulia Zapelloni  1   2 , Elisabetta Caccin  6 , Stefano Fucina  7 , Giorgia Bortolin  8 , Sara Cecco  8 , Paolo Baldo  8 , Sandro Pignata  9 , Daniela Califano  10 , Vincenzo Canzonieri  3   11 , Antonino Ditto  7 , Fabio Puglisi  1   2
Affiliations
Case Reports

Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer

Riccardo Vida et al. Curr Oncol. .

Abstract

Objectives: Endometrial cancer is the most common gynaecologic malignancy, and its mortality rate is rising. Advanced or recurrent disease remains challenging because historically there have been limited therapeutic options. We aim to describe a complete and durable response to the HER2-directed antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in a heavily pretreated patient with HER2-positive, mismatch-repair-deficient metastatic serous endometrial cancer. Methods: A 72-year-old woman underwent hysterectomy, bilateral salpingo-oophorectomy, and staging procedures for FIGO stage IIIA, high-grade serous papillary endometrial carcinoma. Tumour profiling revealed dMMR, a p53 abnormal pattern, and HER2 overexpression (IHC 3+). She received carboplatin/paclitaxel plus avelumab, followed by pegylated liposomal doxorubicin and weekly paclitaxel. After progression on paclitaxel, off-label T-DXd was initiated. Molecular data (FoundationOne CDx) were collected, along with and serial imaging and CA125 assessments. Results: The patient developed cough after two cycles of T-DXd; interstitial lung disease was excluded, and treatment resumed with steroid cover. By December 2024, PET/CT demonstrated complete metabolic response, with resolution of vaginal-vault and para-aortic lesions and normalisation of CA125. Real-world progression-free survival exceeded eight months, with ongoing symptom improvement. Treatment was generally well tolerated; the principal adverse event was grade 3 neutropenia requiring dose reduction. No cardiotoxicity or interstitial lung disease occurred. Conclusions: This case illustrates that T-DXd can induce deep and durable remission in HER2-positive, dMMR metastatic serous endometrial cancer after multiple lines of therapy. It adds real-world evidence supporting further investigation of HER2-directed antibody-drug conjugates in gynaecologic malignancies, and underscores the need for confirmatory trials and refined biomarker-driven patient selection.

Keywords: endometrial cancer; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

F.P. reported honoraria for advisory boards, activities as a speaker, travel grants, and research grants from AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Exact Sciences, Gilead, Italfarmaco, Menarini, MSD, Novartis, Pierre Fabre, Pfizer, and Roche outside the submitted work. MB reported honoraria for advisory boards and speaker fees for GSK, Eisai, AstraZeneca, MSD, Roche, and AbbVie outside the submitted work.

Figures

Figure 1
Figure 1
Patient journey timeline.
Figure 2
Figure 2
PET/CT scans before and after 4 cycles of T-DXd.
See this image and copyright information in PMC

References

    1. Monk B.J., Smith G., Lima J., Long G.H., Alam N., Nakamura H., Meulendijks D., Ghiorghiu D., Banerjee S. Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records. Gynecol. Oncol. 2022;164:325–332. doi: 10.1016/j.ygyno.2021.12.008. - DOI - PubMed
    1. Bartoletti M., Montico M., Lorusso D., Mazzeo R., Oaknin A., Musacchio L., Scambia G., Puglisi F., Pignata S. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis. Cancer Treat. Rev. 2024;125:102701. doi: 10.1016/j.ctrv.2024.102701. - DOI - PubMed
    1. Pignata S., Scambia G., Schettino C., Arenare L., Pisano C., Lombardi D., De Giorgi U., Andreetta C., Cinieri S., De Angelis C., et al. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): A multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2023;24:286–296. doi: 10.1016/S1470-2045(23)00016-5. - DOI - PubMed
    1. Pignata S., Califano D., Lorusso D., Arenare L., Bartoletti M., De Giorgi U., Andreetta C., Pisano C., Scambia G., Lombardi D., et al. MITO END-3: Efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy. Ann. Oncol. 2024;35:667–676. doi: 10.1016/j.annonc.2024.04.007. - DOI - PubMed
    1. Meric-Bernstam F., Makker V., Oaknin A., Oh D.-Y., Banerjee S., González-Martín A., Jung K.H., Ługowska I., Manso L., Manzano A., et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J. Clin. Oncol. 2024;42:47–58. doi: 10.1200/JCO.23.02005. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources